Petmed Express Inc: Form 10-Q for the period ended Dec 31, 2025
Filed with the SEC on Feb 5, 2026 and accepted by EDGAR at Feb 5, 2026, 16:10 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-10-01 to 2025-12-31 | $40.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2025-04-01 to 2025-12-31 | $136.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Gross profit | 3 months2025-10-01 to 2025-12-31 | $9.5m | us-gaap:GrossProfit |
| Gross profit | 9 months2025-04-01 to 2025-12-31 | $36.3m | us-gaap:GrossProfit |
| Operating income | 3 months2025-10-01 to 2025-12-31 | −$10.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2025-04-01 to 2025-12-31 | −$53.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-10-01 to 2025-12-31 | $400.0k | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months2025-04-01 to 2025-12-31 | $1.5m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2025-10-01 to 2025-12-31 | $11.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2025-04-01 to 2025-12-31 | $29.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-10-01 to 2025-12-31 | −$10.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months2025-04-01 to 2025-12-31 | −$53.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-10-01 to 2025-12-31 | −$0.50 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2025-04-01 to 2025-12-31 | −$2.55 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-10-01 to 2025-12-31 | −$0.50 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2025-04-01 to 2025-12-31 | −$2.55 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-10-01 to 2025-12-31 | 21,008,521 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2025-04-01 to 2025-12-31 | 20,884,822 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2025-04-01 to 2025-12-31 | −$23.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2025-04-01 to 2025-12-31 | $3.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2025-04-01 to 2025-12-31 | $24.0k | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2025-12-31 | $26.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-12-31 | $48.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-12-31 | $88.0m | us-gaap:Assets |
| Current liabilities | At period end2025-12-31 | $54.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-12-31 | $55.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-12-31 | $32.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001040130-26-000007. Last ingested by Listed: Oct 24, 2026, 15:04 ET. Listed shows no prices and gives no investment advice.